On January 13, GSK announced the acquisition of IDRx for $1.15 billion. IDRx is a Boston-based clinical-stage biopharmaceutical company dedicated to developing precision therapies for the treatment of GIST. Under the agreement, GSK will pay $1 billion upfront, with an additional potential payment of $150 million based on successful regulatory approval milestones. The acquisition includes the lead molecule IDRX-42, a highly selective KIT-TKI being developed as a first-line and second-line therapy for GIST.$1 Billion! GSK Plans to Acquire IDRx, Gaining a Small Molecule KIT Inhibitor）GISTs typically occur in the gastrointestinal tract, with 80% of cases caused by KIT gene mutations that drive the growth, proliferation, and survival of tumor cells (primary or activating mutations). In 90% of patients receiving first-line treatment, new KIT mutations (secondary or resistance mutations) emerge, often leading to recurrence and limited treatment options. Currently, there is no approved TKI that can inhibit all clinically relevant primary and secondary mutations in KIT.IDRX-42 has demonstrated activity against all key primary and secondary KIT mutations, aiming to improve outcomes for GIST patients. This broad mutation coverage, combined with high selectivity that can enhance tolerability, offers the potential for a best-in-class option.GSK Chief Commercial Officer Luke Miels said:"IDRX-42 complements our growing portfolio in the field of gastrointestinal cancers. This acquisition aligns with our approach to acquiring assets that target validated pathways, where significant unmet medical needs remain despite the availability of approved therapies."GSK Chief Scientific Officer Tony Wood said:"We are excited about the early data of IDRX-42 and its unique ability to target all clinically relevant KIT mutations in GIST, which is a major gap in current standard therapies. We look forward to accelerating its development in 2025 to redefine treatment approaches."StrateGIST 1 is the Phase I/Ib clinical trial of IDRX-42 in patients with advanced GIST, and its latest clinical data were presented as an oral report at the 2024 CTOS Annual Meeting. The data showed that IDRX-42 demonstrated favorable anti-tumor activity with manageable safety in patients with advanced GIST. In second-line or more advanced GIST patients, as well as across all KIT mutation subgroups, the objective response rate (ORR) per modified RECIST v1.1 in the overall evaluable population was 29% (n=87), including one complete response (CR) and 24 partial responses (PR). In patients previously treated with one prior therapy, the ORR was 53% (n=15), including one CR and seven PRs.In all patients, at the time of data cutoff, there were two PRs pending confirmation, both of which were subsequently confirmed. New durability data from StrateGIST 1 was also favorable. IDRX-42 was generally well tolerated, with treatment-related adverse events (TRAEs) mostly low-grade at the recommended Phase Ib dose.IDRx CEO Tim Clackson stated:"Given the lack of significant progress in standard therapies over the past 20 years, we look forward to collaborating with GSK to advance IDRx-42 for GIST patients. Combining our experience to date with GSK's expertise in gastrointestinal cancers, global clinical development capabilities, and strong commercial presence in oncology will help accelerate the development of this novel drug."GSK has an increasing portfolio of products in development targeting significant medical needs in gastrointestinal cancers, including ongoingdostarlimab And the trial of GSK5764227 (GSK'227), GSK 5764227 is an antibody targeting B7-H3.ConjugationMedicine. The agreement reflects GSK's combination approach to identifying potentially best molecules with targeted mechanisms of action. The deal supports GSK's ambition to achieve growth beyond 2031.Under the terms of the agreement, GSK will acquire 100% of the issued shares of IDRx (including all options and other incentive shares) for up to $1.15 billion in cash consideration, comprising a $1 billion upfront payment and potential additional payments of $150 million based on successful regulatory approval milestones. GSK will also be responsible for making success-based milestone payments to Merck KGaA, as well as tiered royalties on IDRX-42.IDRx's investors include venture capital firms Andreessen Horowitz and RA Capital, as well as private equity giant Blackstone Group.IDRxThe last valuation was $430 million in a funding round in August of last year.IDRx was incubated by Borisy Labs in 2021, completed a $122 million Series A financing in 2022, and closed a $120 million Series B financing in August 2024.
Alexis Borisy
Alexis BorisyIs a leading biotechnology entrepreneur and investor with over 25 years of experience in building, operating, and investing in innovative science companies to make a positive impact on the world. Alexis is currently the founder and executive chairman of EQRx, a new pharmaceutical company committed to producing innovative medicines at extremely low prices for the benefit of humanity and society. In addition to co-founding IDRx, Alexis also co-founded Foundation Medicine, serving as its first CEO and chairman, remaining on the board until it was acquired by Roche for $5 billion. He also co-founded Blueprint Medicines, serving as interim CEO. Additionally, Alexis is the co-founder and CEO of Relay Therapeutics; Tango Therapeutics.Founding Investors andChairman. As a partner of Third Rock Ventures for a decade, Alexis was also the founding investor of Editas, Revolution Medicines, Magenta Therapeutics, and Celsius Therapeutics, as well as an investor in companies like insitro and Thrive Early Detection.He founded his first company, CombinatoRx, in his 20s, serving as CEO and taking the company public on NASDAQ. He was personally involved in financing and business development deals worth tens of billions of dollars and authored numerous scientific papers and patents.Currently serves as the Chairman of the Board of the Boston Museum of Science, and has served as a member of the BIO Board of Directors and as the President of the National Venture Capital Association.Graduated from the Department of Chemistry and Chemical Biology at Harvard University, he was a pre-doctoral fellow of the Howard Hughes Medical Institute and was awarded the MIT Technology Review Innovators title.He was also selected as the New England Entrepreneur of the Year in the life sciences category, awarded the Presidential Scholar honor, and holds an undergraduate degree in chemistry from the University of Chicago.
IDRx is conducting targeted therapy for patients with a type of cancer known as gastrointestinal stromal tumor.IDRX-42 (Previously M4205)The early Phase 1/1b trial, the tumor affects 4,000 to 6,000 people annually in the United States.Follow the official account below to explore the world with you!
